Yale Center Beijing and the Shanghai Jiao Tong University-Yale Joint Center for Biostatistics jointly invite you to a discussion with Dr. Dongfeng Tan, Professor at The University of Texas MD Anderson Cancer Center, Yale H.S. '98.

Time and Location

Saturday, June 18, 2016
Registration: 2:30 – 3:00pm
Remarks and Q&A: 3:00 – 4:30pm

Yale Center Beijing
8 Jianguomenwai Avenue, 36th Floor, Tower B, IFC Building (Yong’anli Station, Exit C)

Registration

Ticket: RMB 15 for students; RMB 60 for others.

Click HERE to register via EventBank.

Please email yalecenterbeijing@yale.edu if you have any questions, or call Yale Center Beijing at (10) 5909 0200.

The Event

Cancer is a universal problem. Its prevention, early detection and clinical treatment are major tasks for our generation and beyond, as is raising general public awareness thereof. While rapid advances in molecular and genotyping technology are enabling the formulation of precision drugs for cancer management, a more humanitarian, multidisciplinary approach is also essential for achieving an optimum outcome for patients: prolonged lifespan, increased quality of life, and a greater sense of contentment and psychological well-being. Increasingly detailed analyses of human genetic variation, made possible by a new generation of sequencing techniques combined with big data analysis, present opportunities for a better scientific understanding of cancer as well as for developing and implementing comprehensive new strategies and modes of personalized medicine. They also present a number of practical challenges. Dr. Tan will explore these challenges and opportunities with examples from ongoing studies.

The language of the event will be Chinese.

The Speaker(s)

Dongfeng Tan
Dual Professor of Pathology and Medical Oncology at University of Texas MD Anderson Cancer Center

Dongfeng Tan received his initial pathology training in China (Tongji Medical University) and Germany (Essen University). After his residency at Yale University, he completed an oncologic surgical pathology fellowship at Memorial Sloan-Kettering Cancer Center in New York. Dr. Tan holds joint professorships at more than 20 universities worldwide.

His expertise lies in solid-tumor pathology. Dr. Tan’s patient care responsibilities encompass four major areas: evaluation of surgical biopsy specimens, drug efficacy prediction, evaluation of surgically resected cancer specimens, and molecular diagnostic workup of all solid cancers. Dr. Tan has conducted independent and collaborative clinical and translational investigations, and has been a principal investigator (PI) and co-PI of funded research programs. These academic activities have led to over 150 publications.

Currently, he is professor of pathology and laboratory medicine and of medical oncology at the University of Texas MD Anderson Cancer Center. Dr. Tan also serves on the Minority Committee of the American Association for Cancer Research, and on the Pathology and Clinical Trial Committee of the U.S.-China Anticancer Association.